ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
National Cancer Center Hospital
Kashiwa, JapónPublicaciones en colaboración con investigadores/as de National Cancer Center Hospital (16)
2023
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet, Vol. 402, Núm. 10395, pp. 41-53
-
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
Journal of Clinical Oncology
-
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
Cancer Science, Vol. 114, Núm. 3, pp. 1026-1036
2022
-
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
The Lancet Oncology, Vol. 23, Núm. 5, pp. 659-670
2021
-
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 5, pp. 665-677
2020
-
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
Annals of Oncology, Vol. 31, Núm. 1, pp. 88-95
-
Pembrolizumab in microsatellite-instability-high advanced colorectal cancer
New England Journal of Medicine, Vol. 383, Núm. 23, pp. 2207-2218
2019
2018
-
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
Annals of Oncology, Vol. 29, Núm. 3, pp. 602-609
-
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: Exploratory analyses of the RAISE trial and validation in an electronic medical record data set
ESMO Open, Vol. 3, Núm. 3
2017
-
Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial
European Journal of Cancer, Vol. 78, pp. 61-69
-
Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial
Cancer Chemotherapy and Pharmacology, Vol. 80, Núm. 3, pp. 599-608
-
Proxies of quality of life in metastatic colorectal cancer: Analyses in the RECOURSE trial
ESMO Open, Vol. 2, Núm. 5
2016
2015
-
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study
The Lancet Oncology, Vol. 16, Núm. 5, pp. 499-508
-
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
New England Journal of Medicine, Vol. 372, Núm. 20, pp. 1909-1919